First ever guidance for stem cell therapies in animals published
Document gives advice on sterile manufacturing processes for veterinary stem cell medicines
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Veterinary Use (CVMP) recently approved the first ever guidance at European Union (EU) level for stem cell-based medicines for veterinary use, in the form of a question-and-answer document prepared by the CVMP’s Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT). The guidance addresses concerns raised by manufacturers and authorities in regard to the sterility (absence of bacteria, fungi and mycoplasma) of allogenic stem cell therapies in the veterinary sector.
Allogenic stem cell-based veterinary medicines originate from tissues (such as bone marrow or fat) from a donor from the same species of animal, not from the recipient of the cells. These products are manufactured in large batches which need to be sterile as they are administered by injection directly into the body.
Microbiological contamination can occur at various steps, from the initial sampling of the cells and tissues, up to the final product packaging into containers such as vials, syringes or bottles. A crucial step is the sourcing and collection of the stem cells as it is not always possible to fully implement aseptic techniques at this stage. Control for the absence of microorganisms is also key in manufacturing process controls and quality controls of cell preparations at selected stages of production. The guidance provides answers to eight main issues identified by ADVENT to support manufacturers in ensuring sterile and safe stem cell-based therapies for veterinary use.
Until now, no specific guidance on stem cell-based medicines for veterinary use was available from EMA. The CVMP identified the sterility of allogenic stem cell therapies as one of the priority areas where it would be useful and necessary to develop guidance, following a review of the scientific evidence, such as published literature, available guidance on stem cells for medicines for human use, experience gained by the CVMPthrough scientific advice and public consultations. More guidance concerning cell based products and other priority areas such as monoclonal antibodies is under development.
Interest and research activities into novel therapies such as stem cell or gene therapy has gathered speed over the last few years. ADVENT, a group mandated by the CVMPand composed of senior regulatory experts, brings together wide knowledge and expertise on the scientific aspects of veterinary medicines and also on their regulation. It was set up by EMA to provide general guidance on the requirements for authorisation of novel veterinary medicines and engages additional specific expertise for the development of such guidance.
Novel therapies are therapies entirely new to the veterinary sector either because they are genuinely new and have not been previously used in animals, or new only to the veterinary domain, although well known in the context of human medicines.
- Stem cell-based products for veterinary use: Questions and answers on allogenic stem cell-based products for veterinary use: specific questions on sterility
- Scientific guidelines: Novel therapies
- Ad Hoc Expert Group on Veterinary Novel Therapies
- Veterinary regulatory: Innovation in medicines
- Committee for Medicinal Products for Veterinary Use
- Questions and Answers on allogenic stem cell-based products for veterinary use: specific questions on sterility (23/06/2017)
Latest News from
Statement by Executive Vice-President Margrethe Vestager on the Commission's decision to appeal the General Court's judgment on the Apple tax State aid case in Ireland25/09/2020 15:25:00
Statement given by Executive Vice-President Margrethe Vestager on the Commission's decision to appeal the General Court's judgment on the Apple tax State aid case in Ireland.
Why is Parliament calling for new EU revenue-raising powers?25/09/2020 14:33:00
Parliament is calling for new EU revenue sources to invest in Europe’s future and support the Covid-19 recovery without burdening taxpayers.
Hong Kong: Statement by the Spokesperson on the arrest of Joshua Wong and other pro-democracy activists25/09/2020 13:25:00
The arrest of Hong Kong pro-democracy activist Joshua Wong on 24 September is the latest in a troubling series of arrests of pro-democracy activists since the summer.
ESMA Consults On MIFIR Reference Data And Transaction Reporting25/09/2020 12:38:00
The European Securities and Markets Authority (ESMA), the EU’s securities markets regulator, yesterday launched a Consultation Paper (CP) reviewing the reference data and transaction reporting obligations under the Market in Financial Instruments Regulation (MiFIR).
MEPs question whether the new Migration Pact will bring about real change25/09/2020 11:33:00
The new Migration Pact is insufficient for the majority of EP groups. Some demand compulsory relocation of refugees; others want a firmer stance on irregular arrivals.
Questions and Answers: Coronavirus and the EU Vaccines Strategy25/09/2020 09:25:00
On 17 June, the European Commission presented a European strategy to accelerate the development, manufacturing and deployment of vaccines against COVID-19.
European Centre for Disease Prevention and Control's new risk assessment shows need to step up coronavirus response in the EU24/09/2020 17:02:00
Today, the European Centre for Disease Prevention and Control (ECDC) published its updated risk assessment regarding the COVID-19 pandemic, alongside a set of guidelines for non-pharmaceutical interventions (such as hand hygiene, physical distancing, cleaning and ventilation).
Artificial intelligence: threats and opportunities24/09/2020 16:33:00
Artificial intelligence (AI) affects our lives more and more. Learn about the opportunities and threats for security, democracy, businesses and jobs.
Tourism Committee MEPs: EU must act, 22 million jobs are at stake24/09/2020 15:25:00
Members of Parliament’s Tourism Task Force reiterate that the tourism sector needs EU-level coordination and substantial support to give SMEs a chance of survival.